NASDAQ:BIIB Biogen Q3 2025 Earnings Report $149.89 -0.19 (-0.13%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$149.04 -0.84 (-0.56%) As of 10/24/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Biogen EPS ResultsActual EPSN/AConsensus EPS $3.89Beat/MissN/AOne Year Ago EPSN/ABiogen Revenue ResultsActual RevenueN/AExpected Revenue$2.34 billionBeat/MissN/AYoY Revenue GrowthN/ABiogen Announcement DetailsQuarterQ3 2025Date10/30/2025TimeBefore Market OpensConference Call DateThursday, October 30, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Biogen Earnings HeadlinesBiogen Licenses Vanqua Bio’s Immunology Drug In $1.06B DealOctober 24 at 2:59 PM | msn.comCan Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?October 24 at 2:59 PM | finance.yahoo.comIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of customer deposits as Americans rush into a new form of money… That’s just been authorized under President Trump’s highly controversial new law, S.1582.October 25 at 2:00 AM | Banyan Hill Publishing (Ad)Biogen's Immunology Pipeline Has Long-Term Potential: AnalystOctober 24 at 1:10 PM | benzinga.comBiogen’s Strategic Acquisition of Vanqua Bio’s Asset Bolsters Immunology Portfolio, Justifying Buy RatingOctober 24 at 11:11 AM | tipranks.comBiogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billionOctober 24 at 8:30 AM | reuters.comSee More Biogen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biogen and other key companies, straight to your email. Email Address About BiogenBiogen (NASDAQ:BIIB) is a biotechnology company focused on the discovery, development and delivery of therapies for neurological, autoimmune and rare diseases. The company’s marketed portfolio includes multiple sclerosis treatments such as Avonex, Tysabri (developed in collaboration with Elan Pharmaceuticals) and Tecfidera, as well as Spinraza for spinal muscular atrophy. In addition to its established products, Biogen offers Vumerity and Fampyra to address the needs of patients with various neurodegenerative and neuromuscular conditions. Beyond its commercial portfolio, Biogen maintains an active research and development pipeline targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and other central nervous system disorders. The company has pursued innovative modalities including antisense oligonucleotides and monoclonal antibodies, often entering strategic partnerships to advance late-stage clinical candidates. Biogen’s commitment to neuroscience research is supported by collaborations with academic institutions and biotechnology firms around the world. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen operates in key biopharmaceutical markets across North America, Europe, Japan and emerging regions. The company’s global infrastructure encompasses research facilities, manufacturing sites and commercial offices, enabling it to serve patients and healthcare providers in more than 90 countries. Led by an executive management team with deep industry expertise, Biogen continues to invest in science-driven innovation aimed at transforming the standard of care for neurological and rare disease patients.View Biogen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
